BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19060241)

  • 1. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation.
    Jackson SC; Sinclair GD; Cloutier S; Duan Z; Rand ML; Poon MC
    Blood; 2009 Apr; 113(14):3348-51. PubMed ID: 19060241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
    Shen MC; Lin JS; Lin DS; Hsu SC; Lin B
    Thromb Res; 2003; 112(5-6):291-5. PubMed ID: 15041272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3.
    Casari C; Berrou E; Lebret M; Adam F; Kauskot A; Bobe R; Desconclois C; Fressinaud E; Christophe OD; Lenting PJ; Rosa JP; Denis CV; Bryckaert M
    J Clin Invest; 2013 Dec; 123(12):5071-81. PubMed ID: 24270421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetics of type 2 von Willebrand disease.
    Fressinaud E; Mazurier C; Meyer D
    Int J Hematol; 2002 Jan; 75(1):9-18. PubMed ID: 11843298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
    Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
    Frontroth JP; Hepner M; Sciuccati G; Feliú Torres A; Pieroni G; Bonduel M
    Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets.
    Casari C; Paul DS; Susen S; Lavenu-Bombled C; Harroche A; Piatt R; Poe KO; Lee RH; Bryckaert M; Christophe OD; Lenting PJ; Denis CV; Bergmeier W
    Blood Adv; 2018 Jun; 2(12):1417-1428. PubMed ID: 29925524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia).
    Penas N; Pérez-Rodríguez A; Torea JH; Lourés E; Noya MS; López-Fernández MF; Batlle J
    Am J Hematol; 2005 Nov; 80(3):188-96. PubMed ID: 16247740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2B vWD: the varied clinical manifestations in two kindreds.
    Mathew P; Greist A; Maahs JA; Lichtenberg EC; Shapiro AD
    Haemophilia; 2003 Jan; 9(1):137-44. PubMed ID: 12558793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
    Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
    Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.